Multiple myeloma (MM, plasma cell myeloma) is a malignant hematologic disease
characterized by the clonal proliferation of malignant plasma cells. The treatment of MM has …

In the era of new and mostly effective therapeutic protocols, multiple myeloma still tends to
be a hard-to-treat hematologic cancer. This hallmark of the disease is in fact a sequel to drug …

Pegylated liposomal doxorubicin (Caelyx™, Doxil®) represents an improved formulation of
conventional doxorubicin, with reduced cardiotoxicity and an improved pharmacokinetic …

Effectively treating patients with multiple myeloma is challenging. The development of
therapeutic regimens over the past decade that incorporate the proteasome inhibitor …

The phenomenon of multidrug resistance (MDR) in cancer is associated with the
overexpression of the ATP-binding cassette (ABC) transporter proteins, including multidrug …

Recent pharmacogenomic/pharmacogenetic (PGx) studies have disclosed important roles
for drug transporters in the human body. Changes in the functions of drug transporters due …

Bromodomain and extraterminal (BET) domain containing protein (BRD)-4 modulates the
expression of oncogenes such as c-myc, and is a promising therapeutic target in diverse …

Multiple myeloma (MM) is a malignant neoplastic cancer of the plasma cells that involves the
bone marrow. The majority of patients with MM initially respond to chemotherapy, but they …

The most frequent drawback of doxorubicin is the onset of drug resistance, due to the active
efflux through P-glycoprotein (Pgp). Recently formulations of liposome-encapsulated …

Multiple myeloma (MM) is a hematological malignancy that remains incurable because most
patients eventually relapse or become refractory to current treatments. Although the …